10-K: OpGen Pivots to FinTech, Reports 52% Revenue Growth

OpGen, Inc. has undergone a significant strategic shift from precision medicine to financial technology, reporting a 52% increase in total revenue for 2024 driven by new listing sponsorship services.

Summary

• OpGen, Inc. (OpGen) completed a strategic repositioning in 2024, shifting from a precision medicine company focused on infectious disease to operating in the financial services and technology industry.
• The company's former subsidiaries, Curetis GmbH and Ares Genetics GmbH, filed for insolvency in November 2023 and were subsequently deconsolidated from OpGen's financial statements.
• All assets of Curetis were sold to Camtech Pte Ltd. in April 2024, and all assets of Ares Genetics were sold to bioMerieux S.A. in April 2024, with OpGen not anticipating any proceeds from these sales.
• OpGen established a wholly-owned subsidiary, CapForce International Holdings Ltd. (CapForce), which launched a new business line offering listing sponsorship and consultancy services to international companies seeking to list securities.
• CapForce also plans to launch a next-generation global digital investment banking platform for cross-border securities trading, computational model-enabled advisory, and FinTech-enabled cap table management.
• Total revenue for the year ended December 31, 2024, increased by $1.8 million (52%) to $5,196,149, primarily due to $5,000,000 in listing sponsorship services revenue.
• This increase was partially offset by a significant decrease in product sales (down 93% to $169,373), laboratory services (down 83% to $26,776), and collaboration revenue (down 100% to $0) due to the scaling down of legacy operations and deconsolidation of subsidiaries.
• Total operating expenses decreased by 86% from $34.2 million in 2023 to $4.9 million in 2024, mainly due to the exclusion of Curetis and Ares Genetics expenses and reduced legacy operations.
• The company reported a net income of $11,992,780 for 2024, a significant improvement from a net loss of $32,668,530 in 2023.
• This net income was largely driven by non-operating gains, including a $9.7 million gain on extinguishment of debt, a $2.1 million gain on impairment adjustment, and a $0.6 million gain on settlement of compensation expenses.
• Cash and cash equivalents were $1.3 million at December 31, 2024, up from $1.2 million at December 31, 2023.
• OpGen's common stock was delisted from Nasdaq on August 20, 2024, due to non-compliance with the minimum stockholders' equity requirement and now trades on the OTC Markets under the symbol OPGN.
• The company has a concentration of revenue from one client contract, which represented 96% of total revenues for the year ended December 31, 2024.
• AEI Capital Ltd. and its affiliates own approximately 75.9% of OpGen's outstanding common stock as of July 25, 2025, exerting substantial influence over the company's business.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant financial turnaround from a large loss to a net income, driven by strategic repositioning and debt extinguishment. The new business venture shows promise with initial revenue. However, the delisting from Nasdaq, reliance on a single client, and the early stage of the new business introduce substantial risks and uncertainties, preventing a higher score.

Positives

• Total revenue increased by 52% in 2024 to $5.2 million, driven by the new listing sponsorship services.
• The company achieved a net income of $11.99 million in 2024, a substantial turnaround from a $32.67 million net loss in 2023.
• Significant non-operating gains were recognized, including a $9.7 million gain on extinguishment of debt and a $2.1 million gain on impairment adjustment.
• Operating expenses decreased by 86% to $4.9 million in 2024, primarily due to the deconsolidation of former subsidiaries and scaling down of legacy operations.
• The company secured additional financing rights of up to $7.0 million from AEI Capital Ltd. until December 31, 2025, providing liquidity support.
• The new CapForce subsidiary is strategically positioned in the growing financial services and technology industry, particularly targeting Asian markets for public listings.

Negatives

• Product sales, laboratory services, and collaboration revenue from legacy precision medicine operations significantly decreased or ceased following the insolvency of subsidiaries.
• The company's common stock was delisted from Nasdaq on August 20, 2024, due to non-compliance with listing requirements, and now trades on the OTC Expert Market with limited liquidity.
• OpGen has a history of significant net losses and negative operating cash flows, with uncertain future profitability despite the recent net income driven by non-operating gains.
• The company is highly dependent on a single client contract, which accounted for 96% of total revenues in 2024, posing a concentration risk.
• The insolvency proceedings of former subsidiaries Curetis and Ares Genetics resulted in the company not receiving any proceeds from their asset sales, as funds were allocated to creditors.
• The company has limited operating experience in its new financial services and technology industry, which may present unforeseen challenges.

Risks

• Limited operating experience in the new financial services and technology industry may hinder effective execution and market presence.
• Failure to effectively manage growth and adapt to new market dynamics could adversely affect business, financial condition, and results of operations.
• Uncertain future profitability due to business repositioning, with no guarantee of sustained positive financial results.
• Dependence on key personnel and the ability to attract, retain, motivate, and integrate highly skilled personnel in the new industry.
• Concentration of revenues from one client contract poses a material adverse effect risk if the client fails to fulfill obligations or additional clients are not identified.
• Concentration of common stock ownership by AEI Capital Ltd. (75.9%) allows substantial influence, potentially conflicting with other stockholders' interests and delaying change of control.
• Security breaches, data loss, and other disruptions could compromise sensitive information, leading to substantial remediation costs, reputational damage, regulatory actions, and litigation.
• Systems failures and interruptions in platform availability could adversely affect business, financial condition, and results of operations.
• Reliance on Internet, mobile, and other infrastructures not under company control could interfere with platform speed and availability.
• Counterparty risks, where failure of counterparties to meet obligations could negatively impact results of operations and cash flows.
• Inability to maintain effective internal control over financial reporting could lead to loss of investor confidence and negatively affect stock price.
• High volatility and low trading volume of common stock, exacerbated by OTC Expert Market listing, making it difficult for investors to buy or sell shares.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell shares, potentially depressing the stock price.
• Exercise of outstanding common stock purchase warrants and stock options will have a dilutive effect on existing stockholders' percentage ownership.
• No anticipation of paying dividends in the foreseeable future, making capital appreciation the sole source of gain for investors.
• Unstable market and economic conditions, including inflation and geopolitical conflicts, may have serious adverse consequences on business, financial condition, and stock price.
• Potential for litigation or government investigations, which could result in substantial costs and diversion of management resources.

Future Outlook

OpGen anticipates funding its operations primarily through financing arrangements with AEI Capital Ltd. and plans to apply for relisting with The Nasdaq Stock Market LLC after meeting relevant listing requirements. The new CapForce subsidiary aims to grow its capital market listing sponsorship services, particularly for Asian issuers targeting global exchanges, and launch a next-generation global digital investment banking platform supporting cross-border securities trading, computational model-enabled advisory, and FinTech-enabled cap table management. The company expects to achieve scale and liquidity through public listings for its clients and aims to serve as a trusted partner to future publicly listed market leaders.

Management Comments

• We believe that our current cash and our access to additional cash under the August 2024 Securities Purchase Agreement will allow the Company to fund operations in excess of 12 months from the issuance date of these financial statements.
• The Company plans to propose a new equity incentive plan at the upcoming Annual Meeting of stockholders.
• The Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.

Industry Context

OpGen's pivot to financial services and technology, particularly digital investment banking and listing sponsorship, aligns with the growing trend of digitalization in financial markets and the increasing demand for cross-border capital market access, especially from high-growth Asian enterprises. The global financial advisory services market is projected to grow at an 8.7% CAGR through 2030, reaching $204 billion. The filing highlights Asia-Pacific's dominance in international listings (74% for H1 2025) and the significant presence of foreign private issuers on U.S. exchanges (62% of IPOs in H1 2025). This shift positions OpGen to capitalize on the demand for institutional-grade infrastructure and advisory services connecting local private markets with global public exchanges, particularly for mid-sized companies seeking IPOs or direct listings with market capitalizations between $1 billion and $10 billion.

Comparison to Industry Standards

• The company's new business model, CapForce, targets mid-sized, growth-stage private companies with anticipated market capitalizations between $1 billion and $10 billion for public listings on NYSE, NASDAQ, and major Asian exchanges. This positions it to serve a segment that traditional major global investment banks, which dominate high-profile IPOs and large-cap listings, may overlook due to high fee structures and selective deal criteria.
• CapForce aims to differentiate itself from traditional investment banks and boutique advisory firms by offering flexible, technology-enabled support and integrated service models, including digital equity management and automated investor onboarding, similar to emerging fintech platforms.
• The company's strategy to leverage AEI Capital Ltd.'s network and establish strategic partnerships across Southeast and East Asia is a common approach for new entrants to build trust and navigate jurisdiction-specific regulatory environments in relationship-driven cultures, contrasting with the established regulatory relationships of major global banks.
• The focus on cross-border securities trading and digital asset support within a regulated framework positions CapForce to bridge traditional and digital asset ecosystems, a growing area where many existing platforms may operate in silos.
• The company's reliance on a single client for 96% of its 2024 revenue in the new business segment is a significant concentration risk, which is not typical for established financial advisory firms that usually have a diversified client portfolio.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any claim or litigation that would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. However, litigation can have an adverse impact due to defense and settlement costs and diversion of management resources.

Related Party Transactions

• In March 2024, the company entered into a securities purchase agreement with David E. Lazar (then CEO, Chairman, and Director) to sell 3,000,000 shares of Series E Convertible Preferred Stock for $3.0 million.
• In July 2024, Mr. Lazar sold his Series E Preferred Stock and rights to AEI Capital Ltd., the company's controlling stockholder.
• On January 2, 2024, AEI Capital Ltd. entered into a Letter of Engagement with a privately held company (the Client) to provide listing advisory services, for which AEI Capital was entitled to 3.5% of the Client's equity and $200,000 cash.
• On October 2, 2024, CapForce (OpGen's subsidiary) entered into an Assignment Agreement with AEI Capital, where AEI Capital assigned rights to 2.1% of the Client's equity and $120,000 cash to CapForce.
• As a result of this assignment, CapForce recognized $5.0 million in revenue from the Client's equity in Q4 2024. John Tan Honjian, CEO of both AEI Capital Ltd. and OpGen, Inc., serves on the Client's Board, making the Client a related party.
• In August 2024, the company entered into a Securities Purchase Agreement with AEI Capital Ltd., granting the right to sell up to $3.0 million in common stock. This was amended in October 2024 to allow for an aggregate of $9.0 million in common stock sales until December 31, 2025.
• As of December 31, 2024, the company sold $2.0 million in common stock to AEI Capital Ltd. under this agreement.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from past and ongoing capital raises, including the conversion of Series E Preferred Stock into 7,200,000 common shares. The delisting from Nasdaq to OTC Markets reduces liquidity and transparency, potentially impacting share price. The concentration of ownership by AEI Capital Ltd. (75.9%) means minority shareholders have limited influence.
• **Employees:** The company underwent restructuring in November 2023, reducing headcount and scaling down U.S. operations. The new business model requires attracting and retaining skilled professionals in financial technology, investment advisory, and compliance, which could lead to new opportunities but also competitive talent challenges.
• **Customers (legacy):** Discontinuation of precision medicine products and services (Unyvero, Ares Genetics) means former customers will need to find alternative solutions.
• **Customers (new CapForce clients):** Benefit from CapForce's listing sponsorship and consultancy services, aiming to facilitate public listings on global exchanges and provide digital investment banking solutions. The single client concentration indicates high reliance on one relationship.
• **Creditors:** The settlement of the EIB loan guaranty for $2.0 million resolved a significant outstanding liability, benefiting the company by extinguishing a larger debt, but the proceeds from subsidiary asset sales were allocated to their respective creditors, not OpGen.
• **Regulatory Authorities:** The company is subject to various regulatory frameworks in its new FinTech operations (securities laws, data protection, AML/KYC) and must ensure compliance across multiple jurisdictions.

Next Steps

• CapForce will pursue the launch of a next-generation global digital investment banking platform.
• CapForce will continue to actively provide listing sponsorship and listing consultancy services to grow this business line.
• The company plans to propose a new equity incentive plan at the upcoming Annual Meeting of stockholders.
• The company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.
• CapForce will develop and strengthen partnerships with regional venture capital and private equity firms, law firms, accounting specialists, accelerators, and startup platforms across ASEAN, India, and North Asia.
• CapForce will deploy a regionally localized digital marketing strategy, including white papers, webinars, and participation in industry events.
• CapForce will continue to establish strong data governance, cybersecurity, and infrastructure control policies.
• CapForce will implement stringent internal controls, including confidentiality and intellectual property assignment agreements with employees and third-party partners.
• CapForce will actively monitor for unauthorized use or infringement of its IP assets.
• CapForce will evaluate the legal treatment of its model-enabled advisory features within each jurisdiction and collaborate with licensed partners or restrict services where licensing is required.
• CapForce will continuously review and update its data handling and governance policies to remain compliant with evolving regional requirements.
• CapForce will continue to work with international tax consultants and legal advisors to maintain accurate reporting and timely tax filings.
• The company will continue to monitor the potential limitation on NOL carryforwards due to Section 382 or Section 383 of the Code.

Key Dates

Recommendation

OpGen has undergone a radical transformation, shedding its unprofitable precision medicine business and pivoting to FinTech. The reported net income for 2024 is largely due to one-time gains from debt extinguishment and asset adjustments, not sustained operational profitability in the new segment. While the new CapForce venture shows initial revenue and targets a growing market, it is in its very early stages, highly dependent on a single client, and faces significant execution risks in a competitive industry where the company has limited prior experience. The delisting from Nasdaq to the OTC Expert Market severely impacts liquidity and investor confidence. The substantial ownership concentration by AEI Capital Ltd. also introduces governance considerations. Given the high uncertainty surrounding the new business's long-term viability and the significant market risks, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to diversify its client base, demonstrate consistent operational profitability in FinTech, and potentially relist on a major exchange before considering a 'buy' or 'sell' position.

Keywords

FinTech, Investment Banking, Capital Markets, Listing Sponsorship, Digital Trading Platform, Asset Management, Cap Table Management, SEC Filing, 10-K, Corporate Restructuring, Reverse Stock Split, Nasdaq Delisting, AEI Capital